Cardiol Therapeutics

Cardiol Therapeutics Overview

Founded 2017
Founded
Status Public
Employees 13
Employees
Stock Symbol CRDL
Stock Symbol
Share Price $1.75 (As of Friday Closing)

Cardiol Therapeutics General Information

Description

Cardiol Therapeutics Inc produces pharmaceutical cannabidiol and develops innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Their lead product, CardiolRx, is pharmaceutically produced, manufactured under cGMP, THC free, and designed to be one of the safest and most consistent cannabidiol formulations. An international clinical study of CardiolRx is planned in acute myocarditis, a condition caused by inflammation in heart tissue and the most common cause of sudden cardiac death in young people. The company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol directly to sites of inflammation in the heart that are associated with heart failure.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
TSE
Primary Office
  • Fengate Building, 2275 Upper Middle Road East
  • Suite 101
  • Oakville, Ontario L6H 0C3
  • Canada
+1 (905) 000-0000

Cardiol Therapeutics Timeline

201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cardiol Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.75 $1.68 $1.31 - $4.14 $57.3M 32.8M 95.4K -$0.61

Cardiol Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 51,852 74,907
Revenue 0 0 0
EBITDA (14,942) (12,268) (1,243)
Net Income (14,836) (12,259) (1,279)
Total Assets 13,827 18,124 2,561
Total Debt 150 198 151
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cardiol Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cardiol Therapeutics‘s full profile, request access.

Request a free trial

Cardiol Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
David Elsley Chief Executive Officer & Board Member
Chris Waddick Chief Financial Officer
Anthony Bolton Chief Scientific Officer & Board Member
Thomas Moffatt Executive
Kiernan lynch Executive of Business Development

Cardiol Therapeutics Board Members (9)

To view Cardiol Therapeutics‘s full board member team, request access »
Name Representing Role Since
Anthony Bolton Cardiol Therapeutics Chief Scientific Officer & Board Member 000 0000
David Elsley Cardiol Therapeutics Chief Executive Officer & Board Member 000 0000
Deborah Brown Cardiol Therapeutics Board Member 000 0000
Eldon Smith Cardiol Therapeutics Chief Medical Officer & Chairman 000 0000
Guillermo Torre-Amione MD Cardiol Therapeutics Board Member 000 0000

1 Former Board Member